Literature DB >> 31922475

Transcultural adaptation of the EULAR activity index for primary Sjogren's syndrome in Argentine.

Anastasia Secco1, Lucila Marino1, Natalia Herscovich1, Pedro Aicardi1, Lorena Techera1, Lorena Takashima1, María Lida Santiago1, Felix Romanini1, Marta Mamani1, Antonio C Catalán Pellet1.   

Abstract

OBJECTIVE: To adapt the EULAR Activity Index for primary Sjögren's syndrome (ESSDAI) to the Argentine population.
METHODS: observational, cross-sectional study that included patients in a period of ten months. Three Argentine rheumatologists adapted and translated to Spanish the original version in English and the final version was translated back into English by a research associate whose mother language was English. In order to estimate the constructive validity of the index, the visual analogous scale (VAS) of disease activity was used by experts. A subgroup of patients attended a second visit in order to evaluate test-retest reliability.
RESULTS: 51 patients were included, 49 (96.1%) were female, the median age was 58 ((interquartile range (IQR): 49-69)). The median global VAS was 10 (IQR: 4-22.25) and the median total ESSDAI score was 5 (IQR: 3-9). The correlation between the global VAS and the total ESSDAI score of the scale was 0.79. The intraclass correlation coefficient was 0.67 (95% CI: 0.32-0.92) for the total score and 0.98 (95% CI: 0.92-0.995) for the global VAS. The results of the correlation coefficient between the VAS and the scale for each domain were: constitutional symptoms: 0.46; lymphadenopathy: 0.76; glandular: 0.78; joint: 0.61; skin: 1; respiratory: 0.83; renal: 1; muscular:- (no patient had myositis); peripheral nervous system: 0.72; central nervous system: 0.67; hematological: 0.96; biomarkers: 0.86.
CONCLUSION: The results of this study showed that the ESSDAI is a reliable and valid index for this pSS argentinian population.

Entities:  

Year:  2019        PMID: 31922475      PMCID: PMC7002007          DOI: 10.5152/eurjrheum.2019.19143

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  23 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Flares of systemic disease in primary Sjögren's syndrome.

Authors:  R J Stevens; J Hamburger; J R Ainsworth; G Holmes; S J Bowman
Journal:  Rheumatology (Oxford)       Date:  2005-03       Impact factor: 7.580

3.  Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.

Authors:  S J Bowman; N Sutcliffe; D A Isenberg; F Goldblatt; M Adler; E Price; A Canavan; J Hamburger; A Richards; S Rauz; M Regan; K Gadsby; S Rigby; A Jones; R Mathew; D Mulherin; A Stevenson; P Nightingale
Journal:  Rheumatology (Oxford)       Date:  2007-12       Impact factor: 7.580

4.  Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients.

Authors:  Claudio Vitali; Gianluigi Palombi; Chiara Baldini; Maurizio Benucci; Stefano Bombardieri; Michele Covelli; Nicoletta Del Papa; Salvatore De Vita; Oscar Epis; Franco Franceschini; Roberto Gerli; Marcello Govoni; Susanna Maddali Bongi; Wanda Maglione; Sergio Migliaresi; Carlomaurizio Montecucco; Maddalena Orefice; Roberta Priori; Antonio Tavoni; Guido Valesini
Journal:  Arthritis Rheum       Date:  2007-07

5.  Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Roser Solans; María-Teresa Camps; Arnau Casanovas; Bernardo Sopeña; Bernardino Díaz-López; Francisco-Javier Rascón; Rami Qanneta; Guadalupe Fraile; Roberto Pérez-Alvarez; José-Luis Callejas; Mar Ripoll; Blanca Pinilla; Miriam Akasbi; Eva Fonseca; Jesús Canora; María-Elvira Nadal; Gloria de la Red; Inés Fernández-Regal; Iratxe Jiménez-Heredia; Josep-Angel Bosch; María-del-Mar Ayala; Lluisa Morera-Morales; Brenda Maure; Arantxa Mera; Marc Ramentol; Soledad Retamozo; Belchin Kostov
Journal:  Rheumatology (Oxford)       Date:  2013-10-25       Impact factor: 7.580

Review 6.  Primary Sjögren's syndrome activity and damage indices comparison.

Authors:  Ana Campar; David A Isenberg
Journal:  Eur J Clin Invest       Date:  2010-05-17       Impact factor: 4.686

7.  Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.

Authors:  P M Meiners; S Arends; E Brouwer; F K L Spijkervet; A Vissink; H Bootsma
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

8.  Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory.

Authors:  S J Bowman; J Hamburger; A Richards; R J Barry; S Rauz
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

9.  Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).

Authors:  P M Meiners; A Vissink; F G M Kroese; F K L Spijkervet; N Sillevis Smitt-Kamminga; W H Abdulahad; J Bulthuis-Kuiper; E Brouwer; S Arends; H Bootsma
Journal:  Ann Rheum Dis       Date:  2014-01-28       Impact factor: 19.103

Review 10.  EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.

Authors:  Raphaèle Seror; Simon J Bowman; Pilar Brito-Zeron; Elke Theander; Hendrika Bootsma; Athanasios Tzioufas; Jacques-Eric Gottenberg; Manel Ramos-Casals; Thomas Dörner; Philippe Ravaud; Claudio Vitali; Xavier Mariette; Karsten Asmussen; Soren Jacobsen; Elena Bartoloni; Roberto Gerli; Johannes Wj Bijlsma; Aike A Kruize; Stefano Bombardieri; Arthur Bookman; Cees Kallenberg; Petra Meiners; Johan G Brun; Roland Jonsson; Roberto Caporali; Steven Carsons; Salvatore De Vita; Nicoletta Del Papa; Valerie Devauchelle; Alain Saraux; Anne-Laure Fauchais; Jean Sibilia; Eric Hachulla; Gabor Illei; David Isenberg; Adrian Jones; Menelaos Manoussakis; Thomas Mandl; Lennart Jacobsson; Frederic Demoulins; Carlomaurizio Montecucco; Wan-Fai Ng; Sumusu Nishiyama; Roald Omdal; Ann Parke; Sonja Praprotnik; Matjia Tomsic; Elizabeth Price; Hal Scofield; Kathy L Sivils; Josef Smolen; Roser Solans Laqué; Serge Steinfeld; Nurhan Sutcliffe; Takayuki Sumida; Guido Valesini; Valeria Valim; Frederick B Vivino; Cristina Vollenweider
Journal:  RMD Open       Date:  2015-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.